Yiling Pharmaceutical's G201-Na capsule cleared for clinical trials

Shijiazhuang Yiling Pharmaceutical announced that its clinical trial application for the innovative chemical drug, G201-Na Capsule, has been approved by the National Medical Products Administration. The drug, classified as a Category 1 chemical drug, is a small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for use in assisted reproductive technology (ART) to prevent premature ovulation in patients undergoing controlled ovarian hyperstimulation.